[Molecular classification of aggressive B-cell lymphoma].

[Rinshō ketsueki] The Japanese journal of clinical hematology
Daisuke Ennishi

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically highly heterogeneous disease; various molecular genetic abnormalities contribute to DLBCL development. In particular, recent advances in genomics technologies have led to the discovery of unknown genetic abnormalities and gene expression patterns. Based on the identified pathophysiologies, molecular sub-classification of DLBCL has been progressing. These are important for the discovery of new therapeutic agents and the planning of clinical trials and should be recognized by clinicians as the basis of future personalized medicine.

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

[Rinshō ketsueki] The Japanese journal of clinical hematology
Ken Ohmachi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
I S Lossos
© 2021 Meta ULC. All rights reserved